i.这是本公号第92篇
ii. ETH 打赏地址： 0xC3d06bfbd3B31935e00f810cc4c8F52991d9C75B
Growth and ROIC Drive Value (Fundamental Principles of Value Creation)
源于二级上市公司公开披露信息，不同生物医药公司分析师路演幻灯大致会有几种类别：季度/年度业绩报告、投资者关系路演、研发日/科学日及关键临床研究结果披露等针对研发管线的路演、M&A等投融资相关活动路演。
相较而言，季度/年度业绩报告和投资者关系路演幻灯更容易全面的理解一家公司近来试图对投资者传递的信息，叙事结构和内容设计对于幻灯制作参阅价值也更高。
一般情况下，比较容易理解分析师路演幻灯用于投资者关系的维护，以支持投资者做出合理的投资决策。因而，分析师路演幻灯叙事结构上一般符合金字塔结构化表达特征、内容关系和设置上重于结论、表达上重视简洁清楚。另，和一般演讲功能为主的辅助幻灯不同，分析师路演幻灯一般也具有很好的可读性。
投资者关系路演幻灯
一般情况下，分析师路演及路演幻灯披露，是出于投资者关系的维护，以支持投资分析师可以了解公司的基本情况、业绩、市场情况、发展战略、融资需求以及风险因素，并做出合理的投资决策。
一份较完整的分析师路演幻灯涉及以下要点内容，不同目的和背景下的路演幻灯在结构和内容设置上会有所倾向、调整。一般情况下，一些New emerging和/或New modalities相关的生物医药公司披露的投资者关系路演幻灯在内容设置上会更完整，例如一些基因治疗/编辑相关新兴二级公司和国内新兴生物医药公司。
一份较完整的分析师路演幻灯涉及以下要点内容：
1、公司概况：介绍公司的基本情况，包括公司名称、发起人、成立时间、所属行业等。
2、产品和服务：介绍公司的主要产品和服务，包括产品的特点和优势，以及公司提供的相关服务。
3、市场情况：介绍公司所处的市场情况，包括市场规模、竞争对手、预测市场趋势等。
4、公司业绩：介绍公司过去几年的业绩情况，包括营收、利润、现金流量等数据。
5、发展战略：介绍公司的发展战略，包括新产品的研发、市场拓展、人才引进等方面。
6、融资需求：介绍公司融资的需求，包括融资金额、用途、还款来源等。
7、联系方式：提供公司联系方式，包括电话、邮箱、官网等，以便投资分析师进一步了解公司情况。
1、整理信息：把公司的相关信息整理起来，包括公司的基本情况、业绩、市场情况、发展战略、融资需求等。这些信息将作为PPT的主要内容。
2、设计框架：确定PPT的结构框架，包括页面数量、每页的主题、信息的展示方式等。设计框架时，要注意让PPT的内容清晰易懂，方便投资者理解。
3、编写内容：根据整理的信息，逐页编写PPT的内容。编写内容时，要注意表达清楚、简洁明了，避免陈述模糊、冗长累赘。
4、设计版式：设计PPT的版式，包括页面背景、字体大小、颜色搭配、图片选择等。设计版式时，要注意让PPT看起来美观大方，吸引投资者的眼球。
5、排版布局：对PPT的排版布局进行调整，使信息之间的关系清晰易懂，方便投资者整体理解以做出合理的投资决策。New emerging参阅（ZaiLab 投资者关系幻灯结构摘取局部参阅）
New modalities参阅 （BioNTech 投资者关系幻灯结构摘取局部参阅）
业绩披露分析师路演幻灯
一般情况下，不同于分析师路演幻灯，业绩披露分析师路演幻灯更为清爽简洁，结构内容也更为统一。
业绩披露分析师路演幻灯叙事结构上更倾向于金字塔结构化叙事，这类幻灯很多MNC生物医药公司公开披露的路演幻灯都具有很好的参阅学习价值。
业绩披露分析师路演幻灯在框架结构较为统一，一般情况下涉及下述5块内容：
1、业绩回顾和/或亮点项目、投融资等策略要点回顾；2、关键研究和管线进展披露；3、财务更新回顾；4、下阶段展望；5、附录：管线等。
MNC参阅（Pfizer业绩披露分析师路演幻灯结构摘取局部参阅）
MNC参阅（Novartis业绩披露分析师路演幻灯结构摘取局部参阅）
New emerging参阅（Innovent业绩披露分析师路演幻灯结构摘取局部参阅）
New modalities参阅（Moderna业绩披露分析师路演幻灯结构摘取局部参阅）
下述涉及MNC局部参阅、New emerging局部参阅、New modalities局部参阅生物医药公司路演传递，结合相应年度报告，摘取的策略内容，供参阅：Pfizer
Bringing Breakthroughs to Patients in Need: Pfizer’s growth strategy is driven by five “Bold Moves” that help us deliver breakthroughs for patients and create value for shareholders and other stakeholders. Over the course of 2021, we have made important progress on these Bold Moves. - Unleash the Power of Our People. - Deliver First-in-Class Science. - Transform our Go-to-Market Model. - Win the Digital Race in Pharma. Our strategy is to build a focused medicines company powered by technology leadership in research and development, world-class commercialization, global access and data science. As we implement this strategy, we have five priorities to help shape our decision-making and ensure we continue to deliver on our purpose. Our strategic priorities:
- Deliver transformative innovation
- Embrace operational excellence
- Go big on data and digital
- Unleash the power of our people
- Build trust with society
Our strategy is straightforward. We: Are science and innovation led; Are focused on our chosen disease areas: Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)); and Rare Disease; Have a diversified portfolio with broad coverage across primary, specialty care and rare disease; Have global strength with balanced presence across regions; Have a commitment to people and society. We have three priorities designed to deliver our strategy:
- Accelerate Innovative Science
- Deliver Growth and Therapy Area Leadership
- Be a Great Place to Work
Our stated strategy today is to make Zai Lab a leading global biopharmaceutical company, developing and commercializing medicines for patients not only in China but around the world.
We were founded to fight cancer with a belief that millions of people around the world still have limited or no access to high-quality, innovative, and affordable medicines. We also believe that the industry is in a time of fundamental change driven by regulatory policy updates, scientific progress, and globalization. To seize this opportunity, we have built key competitive advantages in research, clinical development, commercialization, and manufacturing that are designed to drive our business into the future. We intend to continue to expand our competitive advantages and become a global leader by focusing on the following key strategic imperatives: - Research and innovation focus. - World-class clinical development.To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people. To be one of the world’s leading biopharmaceutical companies.
New modalities局部参阅
We aim to further expand and develop our pipeline to strengthen our position as a 21st century immunotherapy powerhouse: Focus on high medical needs; Democratize access to novel medicines.- Fully Integrated Biotechnology Company - Technology-agnostic Multi-Platform Strategy - Diversified Product Pipeline Since our inception in 2008, our vision and mission have remained unchanged. Our vision: We aim to usher in a new era of immunotherapies and to develop innovative approaches for the treatment of cancer, infectious diseases as well as other severe diseases and also to advance regenerative medicine. Scientific rigor and operational excellence are the principles that guide us on our mission. Our mission: We want to improve the health of people worldwide by harnessing the full potential of the immune system and expanding access to innovative medicine. We believe in scientific rigor, innovation and passion as driving forces. Our basis is our biotechnological innovations, which we use to develop new solutions to problems that in some cases have remained unsolved for decades.Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. What makes us unique: We are bold. We are collaborative. We are curious. We are relentless. Built upon a foundation of: Quality, Integrity, Respect.以往相关参阅：
IR KNs. 花自向阳开，万折必东 HAS 2022 规划赏
IR KNs. limited outlook-2021 FY路演ppt赏
IR KNs. limited outlook-JPM路演的最后一张片子
IR KNs. Dynamics Assumption Model
IR KNs. 研发日路演ppt规划赏
IR KNs. “乱云飞渡仍从容”
IR之捌. 交付式PPT
祝，
君安